Analysis

Trump's Hiking Of FDA User Fees Unlikely To Speed Approvals

Law360, New York (March 16, 2017, 10:23 PM EDT) -- Under the White House's 2018 budget, the fees collected by the U.S. Food and Drug Administration from companies to pay for reviewing drugs and medical devices will more than double, but attorneys say it's up in the air whether this will help achieve the president's goal of speeding up the approval process.

On the campaign trail and in office, President Donald Trump repeatedly blasted the FDA's approval process, most recently calling it "slow and burdensome" in his address to Congress last month. The user fees paid by industry to cover the cost of the FDA reviewing their drugs and medical devices...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!